Last checked at 25 Mar 2024 08:54
FOR RELEASE ON | 25 MARCH 2024 |
Director Declaration
IP Group plc (LSE: IPO) ("the Group"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, confirms that Dr Elaine Sullivan, a Non-Executive Director of the Group, has been appointed as a Non-Executive Director of Zealand Pharma A/S.
This disclosure is made in accordance with LR 9.6.14R of the Listing Rules.
For more information, please contact:
IP Group plc | www.ipgroupplc.com |
Liz Vaughan-Adams, Communications | +44 (0) 20 7444 0062/+44 (0) 7979 853802 |
Portland
| |
Alex Donaldson | +44 (0) 7516 729702 |
Notes for editors
About IP Group
IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxbotica. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
For more information, please visit our website at www.ipgroupplc.com.
ENDS